Asset
SOQUELITINIB
CORVUS PHARMACEUTICALS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03952078 | phase1 | active_not_recruiting | 2019-05-03 | 2026-04-30 | Corvus Pharmaceuticals, Inc. | A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma |
| NCT07828860 | phase1 | recruiting | 2026-09-17 | 2027-12-01 | Corvus Pharmaceuticals, Inc. | Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa |
| NCT06345404 | phase1 | completed | 2024-04-16 | 2026-01-28 | Corvus Pharmaceuticals, Inc. | Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD |
| NCT06561048 | phase3 | recruiting | 2024-10-02 | 2027-11-01 | Corvus Pharmaceuticals, Inc. | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma |
| NCT07441395 | phase2 | recruiting | 2026-02-01 | 2027-06-01 | Corvus Pharmaceuticals, Inc. | Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD |
FDA applications (0)
This company has no applications containing this asset.